Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€37.00

€37.00

-1.210%
-0.45
-1.210%
€55.00
 
24.05.24 / Tradegate WKN: A2GS5D / Name: Dermapharm Holding / Stock / Holding Companies / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Dermapharm Holding SE Stock

A loss of -1.210% shows a downward development for Dermapharm Holding SE.
Our community is currently high on Dermapharm Holding SE with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 55 € shows a positive potential of 48.65% compared to the current price of 37.0 € for Dermapharm Holding SE.
For the coming years our community has positive and negative things to say abot the Dermapharm Holding SE stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.

Dermapharm Holding is a Munich-based pharmaceutical company that develops innovative drug formulations and medical devices. It is listed on the Frankfurt Stock Exchange and has a strong presence in Germany and Europe. The company's product portfolio includes preparations for both prescription and over-the-counter drugs, as well as medical devices used in dermatology and urology. Dermapharm Holding differentiates itself from competitors by focusing on niche markets and developing new products in-house through its research and development activities.

Pros and Cons of Dermapharm Holding SE in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
S********** s********
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Dermapharm Holding SE vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Dermapharm Holding SE -1.210% -1.070% 17.274% -19.073% -13.186% -47.331% -
Emerita Resources 3.290% -7.173% 70.543% 41.026% 17.647% -10.204% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-15

Reviewing Dermapharm Holding's financial statements with the US symbol from the industry of Holding Companies provides an interesting insight into the company's financial health. At first glance, the financials indicate a growing business with a solid foundation, experiencing an increase in total assets and revenues over the years. However, a more in-depth analysis reveals both positive and negative factors affecting the company's financial performance.

Increasing total assets and revenues: Between 2019 and 2021, Dermapharm Holding has demonstrated a consistent increase in total assets, from €1.04 billion to €1.45 billion. This growth sign of a company expanding its resources and capabilities. Additionally, there has been a steady growth in total revenues, climbing from €700.88 million in 2019 to €942.91 million in 2021.

Rising gross profit: Gross profit figures for the company have been on an upward trajectory from €383.72 million in 2019 to €620.69 million in 2021. This expanding margin illustrates that the company is managing its cost of sales effectively, thus retaining more profits to support growth initiatives and other operating expenses.

Comments

Buy Dermapharm Holding SE
Show more

News

EQS-News: Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
EQS-News: Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
EQS-News: Strong organic growth in core markets underscores resilience of Dermapharm Holding SE's corporate strategy
EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
EQS-News: Dermapharm Holding SE fulfils all expectations despite multiple macroeconomic challenges
EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business
EQS-News: Dermapharm Holding SE hits upper end of guidance range for adjusted EBITDA, primarily due to steadily growing international presence in branded business